09995.HK
RemeGen Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 80.00
−1.48%Year over year
Reported trailing growth
- Revenue
- +283.5%
- EBITDA
- +706.1%
- EBIT
- +531.9%
- EPS
- +591.5%
- Free cash flow
- +654.6%
- Operating cash flow
- +934.2%
Forward estimates
Based on analyst estimates
- Revenue
- -29.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +61.6%
- EBITDA
- +136.2%
- EBIT
- +110.7%
- Net income
- +148.3%
- EPS
- +147.3%
- Free cash flow
- +89.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026